Active Biotech Presents Positive Cancer Drug Data
Posted on: Friday, 9 March 2007, 12:00 CST
Active Biotech has presented positive new data from the phase Ib study of TASQ which also established the maximum dose in its treatment of prostate cancer.
By step-wise dose escalation, a safe dose of 1mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose level of 0.5mg/day. This enables a dose of 1 mg/day to be administered in future trials.
The ongoing study comprises patients with hormone-refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of Prostate Specific Antigen (PSA), which is a surrogate marker for tumor progression.
PSA measurements were recorded and three of these five patients exhibited a decrease in absolute PSA levels.
The objective of the TASQ project is to develop a pharmaceutical product that can be administered orally for the long-term treatment of prostate cancer. Phase II studies are scheduled to start during 2007. The Medical Products Agency has approved the new maximum tolerated dose to be used in the continued clinical program of TASQ.
Source: Datamonitor
Related Articles
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- EntreMed Initiates Patient Dosing in Phase I Cancer Trial
- Novartis's Femara Reduces Cancer Recurrence in Women, Finds Study
- Semafore and Multiple Myeloma Research Consortium (MMRC) Dose First Patient in Phase I Study of Targeted PI3 Kinase (PI3K) Inhibitor
- Valeant Pharmaceuticals Announces Availability of Complimentary ``Managing Chemotherapy Side Effects For Dummies'' Cancer Chemotherapy Resource; Special Edition ``For Dummies''(R) Book Now Available for Cancer Chemotherapy Patients and Caregivers
- Drugs equivalent in angina treatment: study
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
- Vitamin E Scare Hurts Cancer Trial; Doctors Say Their Study on Supplement, Prostate Cancer Prevention is Safe
 |
 |
User Comments (0)
RSS Feeds